or Try an Advanced Search...

    Technical Analysis for NKTX - Nkarta, Inc.

    Grade Last Price % Change Price Change
    F 2.50 0.81% 0.02
    NKTX closed up 0.81 percent on Wednesday, November 20, 2024, on 1.23 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NKTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 0.81%
    NR7 Range Contraction 0.81%
    NR7-2 Range Contraction 0.81%
    Doji - Bullish? Reversal 0.81%
    Older End-of-Day Signals for NKTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    Possible Inside Day about 18 hours ago
    Down 3% about 20 hours ago
    Down 2 % about 22 hours ago
    Down 1% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NKTX Chart by TradingView
    Basic chart:

    Profile

    Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Gene Therapy Lymphoma Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell

    Is NKTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Nkarta to Participate in an Upcoming Investor Conference
    Nov 8 Nkarta ending development of asset for lymphoma
    Nov 7 Nkarta GAAP EPS of -$0.39 misses by $0.03
    Nov 7 Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
    Oct 31 Nkarta (NKTX) Stock: Looking For Upside
    Oct 31 Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
    Oct 18 Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
    Oct 9 Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Sep 3 Nkarta to Participate in Upcoming Investor Conference
    Aug 14 Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
    See more NKTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.24
    52 Week Low 2.38
    Average Volume 812,310
    200-Day Moving Average 6.79
    50-Day Moving Average 3.92
    20-Day Moving Average 3.09
    10-Day Moving Average 2.85
    Average True Range 0.29
    RSI (14) 27.54
    ADX 19.64
    +DI 18.85
    -DI 33.11
    Chandelier Exit (Long, 3 ATRs) 3.36
    Chandelier Exit (Short, 3 ATRs) 3.24
    Upper Bollinger Bands 3.80
    Lower Bollinger Band 2.38
    Percent B (%b) 0.08
    BandWidth 45.71
    MACD Line -0.40
    MACD Signal Line -0.37
    MACD Histogram -0.036
    Fundamentals Value
    Market Cap 122.68 Million
    Num Shares 49.1 Million
    EPS -2.50
    Price-to-Earnings (P/E) Ratio -1.00
    Price-to-Sales 1000000.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.71
    Resistance 3 (R3) 2.70 2.62 2.68
    Resistance 2 (R2) 2.62 2.57 2.63 2.66
    Resistance 1 (R1) 2.56 2.53 2.59 2.57 2.65
    Pivot Point 2.48 2.48 2.50 2.49 2.48
    Support 1 (S1) 2.42 2.43 2.45 2.43 2.35
    Support 2 (S2) 2.34 2.39 2.35 2.34
    Support 3 (S3) 2.28 2.34 2.33
    Support 4 (S4) 2.29